Search
MOL-4239
go.drugbank.com/drugs/DB16051InvestigationalMOL-4239 is under investigation in clinical trial NCT01826201 (Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis).
Volinanserin
go.drugbank.com/drugs/DB16351InvestigationalVolinanserin is under investigation in clinical trial NCT00464243 (Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study).
IMT504
go.drugbank.com/drugs/DB17792InvestigationalIMT504, a non-CpG 24-mer oligodeoxynucleotide, is an immunomodulatory oligonucleotide currently being investigated as a rabies vaccine.[A259467]
CEQ508
go.drugbank.com/drugs/DB17911ExperimentalColi Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Ditekiren
go.drugbank.com/drugs/DB19992ExperimentalDitekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemEfzofitimod
go.drugbank.com/drugs/DB16453InvestigationalEfzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody.
TAS-102
go.drugbank.com/drugs/DB08937InvestigationalTrifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.
Candoxatrilat
go.drugbank.com/drugs/DB11623ExperimentalA dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy
Amilomotide
go.drugbank.com/drugs/DB05150InvestigationalIt is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalPMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.